Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Osteosarcoma (OS) is a primary malignant bone tumor, particularly aggressive in children and adolescents.
• Despite therapeutic advances, outcomes for metastatic or recurrent OS remain poor.
• Cisplatin (CDDP) is a key chemotherapy drug for OS, but drug resistance is a significant clinical challenge.

Purpose of the Study:

• To review the critical role of long non-coding RNAs (lncRNAs) in mediating CDDP resistance in osteosarcoma.
• To elucidate the molecular mechanisms and genetic factors contributing to CDDP resistance in OS.
• To provide insights for developing more effective therapeutic strategies against OS.

Main Methods:

• Literature review focusing on lncRNAs and CDDP resistance in osteosarcoma.
• Analysis of gene expression regulation related to lncRNAs in OS.
• Synthesis of current understanding of molecular mechanisms underlying CDDP resistance.

Main Results:

• lncRNAs are significantly involved in the development of CDDP resistance in osteosarcoma.
• Specific lncRNAs influence cellular responses to CDDP treatment.
• Dysregulation of lncRNA expression contributes to therapeutic failure in OS patients.

Conclusions:

• Targeting lncRNAs may offer novel therapeutic avenues to overcome CDDP resistance in osteosarcoma.
• Further research into lncRNA-mediated mechanisms is essential for improving OS treatment outcomes.
• Understanding lncRNA expression patterns can aid in predicting treatment response and guiding therapeutic decisions.